Myoril Plus is a combination medicine that is commonly used when short-term symptomatic assistance is needed in certain clinical contexts. The use of an active component in this medicine is commonly associated with contexts involving heightened systemic burden or symptoms related to physical discomfort. The medicine is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed. It helps manage symptom clusters that may become intense or disruptive, such as symptoms of increased neurological or muscular activity and those that create noticeable physiological strain. It contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes by easing distress. The drug is considered relevant in conditions characterized by periods of heightened symptoms associated with acute or disruptive episodes. It supports general well-being during symptomatic phases, assisting with physical comfort when symptoms interfere with routine activities.

“The medicine is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily.”

---

Quick Fact: Supportive Symptom Management

This medicine is commonly used to help manage symptoms that create noticeable physiological strain or those that affect functional stability.

Who Can and Cannot Use Myoril Plus?

The official eligibility profile for Myoril Plus, a combination of an NSAID (Ketoprofen) and a muscle relaxant (Thiocolchicoside), defines strict population limits and absolute contraindications.

Absolute Contraindications

The medicine is strictly contraindicated in several groups and must not be used by:

• Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception.
• Children and adolescents under 16 years of age.
• Patients with known hypersensitivity to the active ingredients or who have experienced asthma, hives, or allergic reactions to aspirin or other NSAIDs.
• Patients in the setting of peri-operative pain from Coronary Artery Bypass Graft (CABG) surgery.

Restricted and Conditional Use

Use is restricted to a short-term period and is contraindicated for chronic treatment. Patients with existing conditions require caution and medical oversight:

• Individuals with severe renal or hepatic impairment, uncompensated heart failure, or a history of gastrointestinal ulcers or bleeding must use the medicine with extreme caution or avoid it.
• Patients with epilepsy or a risk of convulsions should be administered the medicine with caution.

Interactions with other medicines and products

Official regulatory information for Myoril Plus, a combination of Ketoprofen and Thiocolchicoside, focuses on interaction risks documented for its individual components, particularly the NSAID, Ketoprofen.

Contraindicated Combinations

The NSAID component's use is contraindicated in specific high-risk settings due to interaction risks:

• High-Dose Methotrexate (typically >15 mg/ week): Prohibited due to the risk of increased methotrexate toxicity resulting from reduced clearance.
• Perioperative Pain in the setting of Coronary Artery Bypass Graft (CABG) Surgery: Prohibited due to the increased risk of serious cardiovascular events.

---

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class	Official Regulatory Statement
Anticoagulants/Antiplatelet Agents	Significantly increases the risk of hemorrhage and bleeding events.
Other NSAIDs or high-dose Aspirin	Increases the risk of bleeding and gastrointestinal adverse effects.
Lithium	May cause an increase in plasma lithium levels due to reduced renal clearance.
Diuretics / ACE Inhibitors / ARBs	May decrease the antihypertensive effects and increase the risk of renal impairment.
Other Central Muscle Relaxants	May increase the muscle-relaxing effect and incidence of side effects.

---

Food and Lifestyle Interactions

• Alcohol: Avoid consumption, as it may increase the risk of stomach irritation and other adverse effects.

Population-Specific Cautions

• Elderly Patients: Advised caution due to heightened susceptibility to interaction-related side effects affecting the renal and gastrointestinal systems.
• Renal Impairment: Risk of renal failure is increased when co-administered with diuretics or RAS inhibitors in these patients.

Peripheral Modulation of Inflammatory Mediators

The peripheral action is governed by Ketoprofen, which functions as a non-selective inhibitor of the Cyclooxygenase enzymes ( COX-1 and COX-2). This molecular interference blocks the Arachidonic Acid Cascade, thereby suppressing the synthesis of prostaglandins and other chemical mediators. This molecular action affects physiological signaling at the tissue level by affecting the chemical sensitization of peripheral nociceptors and altering inflammatory mediator pathways.

---

Central Enhancement of Inhibitory Control

The central mechanism is mediated by Thiocolchicoside, which acts primarily as an agonist on Glycine Receptors ( GlyR) within the spinal cord and brainstem. By enhancing this inhibitory neurotransmission, the compound increases the flow of chloride ions, hyperpolarizing motor neurons. This mechanism facilitates a decrease in the hyper-excitability of motor neurons and alters the threshold of polysynaptic motor reflexes.

---

Mechanistic Synergy of Dual-Action

Myoril Plus engages a dual-target, complementary mechanism that simultaneously addresses both peripheral chemical signaling and central neurological response. This synergy involves coordinated modulation of both the eicosanoid synthesis pathways and the central motor reflex pathways, by coordinating the modulation of both peripheral and central pathways in the musculoskeletal system.

How to Use Myoril Plus

This section describes the standard administration protocols for the fixed-dose combination of Ketoprofen and Thiocolchicoside (Myoril Plus). The usage pattern is primarily structured by restrictions placed on the muscle relaxant component, Thiocolchicoside, which limit both the dose and the duration of systemic exposure.

Instruction Entity	Guideline
Route of Administration	Primarily Oral (tablet or capsule) for the fixed combination. The Thiocolchicoside component is also approved separately for Intramuscular (IM) injection.
Maximum Daily Dose	The oral dose is limited to a maximum of 16 mg of Thiocolchicoside per day. This corresponds to a unit dose of 8 mg taken twice daily.
Timing and Frequency	The medicine is administered twice daily (every 12 hours) to comply with the maximum daily limit. The oral form is commonly specified to be taken with food or milk to mitigate gastrointestinal effects of the Ketoprofen component.
Course Duration	Treatment duration is strictly limited to 7 consecutive days for the oral route and 5 days for the intramuscular route, as it is intended only for short-term symptomatic use.
Age-Group Rule	Use is restricted to adolescents 16 years of age and older. The medicine is not recommended for use in children under 16 years of age.

The guidelines establish a controlled protocol, positioning the medicine as a temporary measure. The mandatory twice-daily frequency manages the maximum allowable systemic dose, while the strict time limit of 7 days ensures the medicine is used only for brief symptomatic support. Oral forms must be swallowed whole and not crushed.

Research Evidence / Overview of Studies for Myoril Plus

Evidence for Use in Acute Musculoskeletal Conditions

The available research for Myoril Plus, which is a combination of Ketoprofen and Thiocolchicoside, was studied for conditions associated with acute or disruptive episodes, specifically those characterized by both pain and muscle stiffness or spasm. The evidence base includes pharmacological studies that research examined the structure of combining two pharmacological components for conditions where symptoms of pain are complicated by involuntary muscular activity.

In addition to pharmacological research, there is an official therapeutic overview from the European Medicines Agency (EMA) that contributes to the broader evidence landscape. The findings describe patterns observed in the studies related to outcomes related to acute symptoms, but research does not determine whether an individual will respond similarly.

---

What Outcomes Have Been Examined in Clinical Research?

Studies explored a variety of measurements to determine how symptoms change over time. A key focus was observed in measurements related to outcomes related to physical discomfort, with researchers monitoring changes in acute pain intensity. Other measurements included outcomes reflecting daily functioning or activity level, such as the reported evaluation of muscular tightness and stiffness.

Further research examined patient experiences related to the ability to move and overall physical discomfort, which are patient-reported outcomes describing perceived discomfort. The evidence contributes to the broader evidence landscape by describing patterns of short-term changes that evidence suggests.

---

Long-Term Studies and Follow-up Duration

The available research is largely focused on research exploring short-term symptom changes to provide data for short-term symptomatic assistance. Because the follow-up durations were limited in the key studies and regulatory reviews, evidence providing insight into long-term outcomes is considered insufficient.

Long-term effects are not fully established for this combination, as the initial body of research primarily focuses on short-term periods of increased symptom activity. The EMA's review noted limitations on the permitted duration of use. This structural limitation reflects the current focus on short-term data.

---

Research Limitations and Areas of Uncertainty

The research conducted so far, while contributing to the evidence landscape, contains several notable limitations. A significant finding is that the follow-up durations were limited, meaning that information concerning long-term effects remains scarce. Additionally, the sample sizes were modest in some clinical investigations, and the evidence quality varies across studies, which may lead to findings that were mixed or heterogeneous. Certainty remains low for extending findings beyond the specific conditions and patient populations under which the studies were conducted.

Key Studies & References

1. Ketoprofen: MedlinePlus Drug Information (for NSAID class information and indications)

Common questions about Myoril Plus (FAQ)

---

Q: What is the specific muscle condition Myoril Plus is used to treat?

Official product information, such as the Summary of Product Characteristics (SmPC), indicates that Myoril Plus is used for the symptomatic treatment of painful muscular contractures (muscle spasms). This is typically in the context of acute spinal pathology, meaning sudden or short-term issues affecting the spine. The medicine is for use in adults and adolescents aged 16 years and older, as indicated by regulatory documents.

---

Q: Do I need a prescription to get Myoril Plus?

Based on the regulatory status and the safety profile of its active ingredients—which include a non-steroidal anti-inflammatory drug (NSAID) and a muscle relaxant with specific warnings—Myoril Plus is designated as a Prescription Drug (Rx). In approved countries, its status as a prescription drug means it is obtained through a healthcare professional.

---

Q: What should I do if I miss a dose of Myoril Plus?

Official information on the medicine's label indicates that a double dose should not be taken to compensate for a missed dose. If it is close to the time for your next scheduled dose, you should simply skip the missed dose and wait for your next scheduled time to maintain the proper dosing interval.

---

Q: Can I crush or chew the Myoril Plus tablet?

Regulatory documents state that Myoril Plus tablets or capsules must be swallowed whole with a glass of water and should not be crushed, broken, or chewed. Regulatory documents state that this method of administration is required to maintain the medicine’s intended use and safety.

---

Q: Does Myoril Plus affect my ability to drive or operate machinery?

Official product information notes that Myoril Plus can commonly cause side effects such as drowsiness (somnolence) and dizziness. Regulatory information indicates that patients should avoid driving or operating machinery if they experience these effects, as their concentration or reaction time may be impaired.

---

Q: How soon after taking it should I expect the medicine to start working?

Studies on the components suggest the active ingredients are rapidly absorbed after taking the medicine. The anti-inflammatory component, Ketoprofen, typically achieves its highest level in the blood within 0.5 to 2 hours. The muscle relaxant component also reaches its maximum concentration around 1 hour after being taken.

How to Store and Dispose of Myoril Plus?

The storage and disposal of Myoril Plus, a combination of Ketoprofen and Thiocolchicoside, must follow strict regulatory guidelines to maintain product stability and ensure public safety.

Storage Requirement	Official Instruction
Temperature	Store below 25 C and do not freeze.
Environment	Protect from light and moisture (humidity).
Container	Keep the medicine in its original container.
Safety	Keep the product out of the sight and reach of children.

Handling and Expiry

Do not use the medicine after the expiry date printed on the packaging, and avoid storing it in environments like the bathroom.

Disposal

Official disposal rules mandate that the product must not be discarded via wastewater or household waste. Unused or expired Myoril Plus must be returned to a pharmacist or an authorized local waste collection point for proper pharmaceutical disposal.